Tidepool Loop, an automated insulin dosing app based on one developed by the DIY diabetes community, received FDA clearance in January.
Grassroots innovation: How a patient-driven device for diabetes won FDA clearance Read More »
Tanto en física como en química, la escala mesoscópica se refiere a la escala de longitud en la que se puede estudiar las propiedades de un material o fenómeno, sin tener que discutir el comportamiento de los átomos individuales. En una modelización mesosc&o …
Predecir la flexibilidad de movimiento del ADN a nivel molecular Read More »
Almost two years after its launch, eye-focused gene therapy start-up Vedere Bio II is closing its doors, company leaders announced through a LinkedIn post over the weekend.
Vedere Bio II Closes Doors After Preclinical Studies Fall Short Read More »
El ARN mensajero tiene un gran potencial terapéutico para tratar diversas enfermedades causadas por genes defectuosos. Hasta ahora, uno de los obstáculos para su aplicación ha sido lo difícil que resulta administrarlo en la parte correcta del cuerpo, sin efectos secundari …
Crean nanopartículas para terapias genéticas en los pulmones Read More »
¿Dónde podemos comer el mejor cachopo asturiano en España? Que nuestro país es uno de los que mayor influencia tienen sobre la gastronomía mundial no es ningún secreto para nadie. Históricamente, España siempre ha sido considerada com …
Un restaurante ovetense, en la cima del cachopo asturiano Read More »
Alzamend Neuro, Inc. requests that their press release NewsItemId: 20230403005455 “Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type” be killed.
Aisa Pharma, Inc. a private, clinical-stage biopharmaceutical company, announces that the National Institute of Neurological Disorders and Stroke (NINDS)- National Institutes of Health (NIH) have awarded the Preclinical Screening Pain Platform (PSPP) award to Aisa’s Profervia® (cilnidipine), a once-daily novel, investigational, oral calcium-channel antagonist.
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”) today announced the initiation of a phase I/IIA clinical trial for its immunotherapy vaccine (ALZN002) to treat mild to moderate dementia of the Alzheimer’s type.
Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced positive top-line results from FO2CUS, a study evaluating the efficacy and safety of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, in hemodialysis patients who were converted from a long-acting erythropoiesis-stimulating agent (ESA) to three times weekly oral vadadustat dosing for the maintenance treatment of anemia.
HuidaGene Therapeutics (辉大基因; HuidaGene) announces that the US. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for HG004, HuidaGene’s lead gene replacement therapy for the treatment of inherited retinal disease caused by RPE65 mutations.
HuidaGene Receives Orphan Drug Designation for Gene Therapy of Blindness Read More »
